Effects of probucol and EPA on lipid component of HDL particles

Effects of probucol and EPA on lipid component of HDL particles - Effects of probucol and EPA on lipid component of HDL particles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024187

Enrollment

Registered

2016-11-01

Start date

2016-11-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hypercholesterolemia Dyslipidemia

Interventions

(A)Treatment of probucol(500mg/day)in patients with familial hypercholesterolemia for 4 weeks (B)Treatment of EPA(1800mg/day) in patients with dyslipidemia for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (A)Probucol-treated group Patients with familial hypercholesterolemia who does not take probucol 1)Hyper LDL-cholesterolemia 2)Taking lipid-lowering agents 3)LDL-c<200mg/dl 4)NYHA 1 or 2 5)>20 years old 6)AST<100IU/L, ALT<100IU/L, Cr<1.5mg/dL 7)Informed consent (B) EPA-treated group Patients with dyslipidemia who does not take EPA 1)>20 years old 2)Informed consent

Exclusion criteria

Exclusion criteria: (A)Probucol-treated group 1)Taken probucol previously 2)Taking cyclosporin 3)Allergic to probucol 4)TG>400 mg/dL 5)HbA1c>8% 6)Frequent multifocal premature ventricular contraction 7)Atrial fibrillation 8)QTc>450msec(male),>470msec(female)on the ECG 9)Congestive heart failure or unstable angina 10)Participating in other trials 11)Pregnant (or might be pregnant) or lactating 12)The doctor decided to be inadequate for participating in this trial (B) EPA-treated group 1)Hemodialysis 2)Liver dysfunction 3)Active malignant diseases 4)Scheduled to undergo coronary angiography or CABG 5)Severe heart failure 6)ACS within 3 months 7)PCI or CABG within 3 months 8)HbA1c>8% 9)Secondary dyslipidemia or taking omega3 agents 10)Bleeding or bleeding tendency 11)Having past side effects for omega3 agents 12)Participating in other trials 13)Pregnant (or might be pregnant) or lactating 14)The doctor decided to be inadequate for participating in this trial

Design outcomes

Primary

Measure	Time frame
Changes of lipid species in HDL particles after the treatment of probucol or EPA	—

Countries

Japan

Contacts

Public ContactTohru Ohama

Osaka University Graduate School of Medicine Cardiology

ohama@cardiology.med.osaka-u.ac.jp06-6879-3633

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026